Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Roxadustat and SR-9011 — mechanism, dosing, side effects, legal status, and pricing.
Roxadustat (Evrenzo) is a small-molecule HIF-prolyl-hydroxylase inhibitor — not a peptide — that raises endogenous erythropoietin. It is an approved prescription drug for anemia of chronic kidney disease in China, Japan, and the EU, but the US FDA rejected it over safety signals. Because it boosts EPO/hemoglobin, it is diverted to the gray market for endurance doping and is WADA-prohibited at all times.
SR-9011 is a synthetic small-molecule REV-ERB (Rev-erbα/β) agonist — not a peptide — studied preclinically as a circadian/metabolic modulator. It has no human data of any kind, no regulatory approval, and is WADA-prohibited at all times. Note: it is frequently confused with "Stenabolic," which is properly its analog SR9009, not SR-9011.
Roxadustat
SR-9011
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Roxadustat
No pricing data yet.
Check Roxadustat prices →SR-9011
COA corpus from Disclosed Labs — independently tested batches only.
Roxadustat
3
COAs
99.8%
Avg purity
2
Labs
SR-9011
1
COAs
96.8%
Avg purity
1
Labs
Roxadustat is supported by extensive human data as an approved anemia drug (China 2018, Japan 2019–2020, EU 2021 as Evrenzo) with numerous Phase 2/3 CKD trials. The US FDA advisory committee voted against approval in July 2021, citing thrombosis, seizures, infections, and mortality signals. No validated recreational or performance dose exists. Not FDA-approved; not a peptide.
In diet-induced obese mice (intraperitoneal dosing), SR-9011/SR9009 increased energy expenditure, reduced fat mass, and improved dyslipidemia and hyperglycemia (Solt et al., Nature 2012). Human liver microsome work identified 14 metabolites but no half-life, and the authors caution against human extrapolation. There are no registered human trials of SR-9011; no human safety, dose, or pharmacokinetic data exist.
Roxadustat and SR-9011 are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dosing Notes
Side Effects
Contraindications
Lab Testing
Disclosed Labs